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Background: In patients with acute leukemia, lymphoma and chronic malignancies, donor and/or recipient Epstein-Barr virus (EBV) 
seropositive status increases the risk of development of chronic graft-versus-host disease (cGVHD) after allo-hematopoietic cell trans-
plantation (allo-HCT), while it has no influence on other transplant outcomes. No data are available on the impact of EBV serostatus on 
transplant outcomes in patients with nonmalignant hematological disorders. Objective: We analyzed the influence of the recipient’s (R) 
and donor’s (D) EBV serostatus on transplant outcomes (overall survival (OS); relapse-free survival (RFS); relapse incidence (RI); nonre-
lapse mortality (NRM); acute graft-versus-host disease (aGVHD); cGVHD) in patients with nonmalignant hematological disorders under-
going allo-HCT. Patients and Methods: A total of 2,355 allo-HCTs performed between 1997 and 2016 for acquired bone marrow failure 
or hemoglobinopathies were included in this retrospective Registry megafile Infectious Diseases Working Party of the European Society 
of Blood and Marrow Transplantation (IDWP-EBMT) study. Results: Demographics: The median age of recipient was 17.7 years (range: 
0–77), and 50.8% were children. 79.0% of recipients and 75.4% of donors were EBV-seropositive. 67.8% had HCT from a matched family 
donor, 4.6% from a mismatched family donor, and 27.6% from an unrelated donor (UD). T-cell depletion was performed in vivo and ex 
vivo in 82.2% and 6.6% of patients, respectively. Conditioning regimen was myeloablative in 63.7% and reduced intensity conditioning 
(RIC) in 36.3% of patients. The median follow-up was 4.7 years. Transplant outcomes: EBV-seropositive recipients in comparison with 
EBV-seronegative recipients had lower OS (85.4% vs. 88.4%, p = 0.035) and higher NRM (10.0% vs. 6.4%, p = 0.018). No other significant 
differences were found for: RI, RFS, and aGVHD or cGVHD with respect to EBV pretransplant serostatus donor and/or recipient. Multi-
variate analysis: A trend toward higher risk of development of cGVHD (HR = 1.31; p = 0.081) and better survival (HR = 0.78; p = 0.087) in 
allo-HCT from EBV-seropositive donors was found. Allo-HCT in EBV-seropositive recipients had a trend toward lower risk of development 
of cGVHD (HR = 0.75; p = 0.065). When four subgroups (R−/D−, R−/D+, R+/D−, R+/D+ EBV serology) were analyzed, the EBV serostatus 
had no significant impact on OS, RFS, RI, NRM and development of aGVHD or cGVHD. Conclusions: Allo-HCT from EBV-seropositive 
versus EBV-seronegative donors are at 31% higher risk of cGVHD in patients with nonmalignant hematological disorders undergoing 
allo-HCT; however this difference is nonsignificant in multivariate analysis.
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All rights reserved.
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Introduction
Epstein-Barr virus (EBV) is one of the most common 
human viruses, and the prevalence in adults is about 
84% [1, 2]. In general, the incidence of EBV positivity 
in population is increasing with age and decreasing by 
calendar year. EBV is responsible for the development 
of a number of various diseases, such as post-transplant 
lymphoproliferative disorder (PTLD) and several other 
end-organ diseases, both after hematopoietic cell 
transplantation (HCT) and solid organ transplants (SOT) 
[3]. EBV serostatus of donor (D) and recipient (R) is a 
strong risk factor for the development of PTLD [3, 4]. 
Continuous progress in diagnosis and therapy resulted 
in an increase in the survival rate after PTLD from 16% 
before the year 2000 up to 70% in 2013 [5, 6].
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Recently, it was shown in two studies that EBV is associated with 
the increased risk of chronic graft-versus-host disease (cGVHD). In 
patients with acute leukemias, donor EBV-seropositivity significantly 
increases the risk of chronic, and to lesser extent acute graft-versus- 
-host disease (aGVHD) after allo-HCT, with no significant association 
with other transplant outcomes [1]. In patients with lymphomas or 
chronic malignancies undergoing allo-HCT, it has been shown that 
the risk of development of cGVHD was increased for EBV R+/D+, 
R+/D−, and R−/D+ in comparison with R−/D− transplants, thus an 
EBV-negative recipient with lymphoma or chronic malignancy can 
benefit from the selection of an EBV-negative donor in the context of 
cGVHD, while there are no preferences in donor EBV serostatus for 
EBV-seropositive recipient [7].
Since so far no data were available on the role of serostatus of EBV 
on outcome of HCT in patients with nonmalignant hematological 
diseases, the objective of the study was to analyze the impact of 




A total number of 2,355 patients with nonmalignant hematological 
diseases who underwent allo-HCT between 1997 and 2016 and 
reported to the EBMT Registry were included in this retrospective 
study performed by Infectious Diseases Working Party of the 
European Society of Blood and Marrow Transplantation (IDWP-
EBMT). Diagnosis included acquired bone marrow failure (70.1%) 
or hemoglobinopathies (29.9%). The following criteria of inclusion for 
the study were used based on full data availability on first transplant, 
type of conditioning, source of stem cells (including cord blood), and 
recipient and donor EBV serostatus. The study was performed within 
EBMT according to the Declaration of Helsinki.
Definitions
Overall survival (OS) was calculated as time from allo-HCT to death. 
Death from any cause was regarded as event for OS. Relapse or 
death from any cause were analyzed as an event for relapse-free 
survival (RFS), hereby defined as survival with no evidence of relapse 
or progression. Relapse was considered as the reappearance of 
the primary disease. Relapse incidence (RI) was calculated with 
relapse of the primary disease (in this setting: graft rejection) as 
event and death without relapse as a competing event. Nonrelapse 
mortality (NRM) was defined as death without evidence of relapse 
or progression, with relapse being a competing event. aGVHD was 
graded according to classical criteria by Glucksberg et al. [8], and 
cGVHD was classified as extensive or limited. De novo cGVHD was 
defined for cGVHD occurring without previous aGVHD.
Statistical analyses
The primary endpoint of the study was the probability of OS, 
whereas RI, RFS, NRM, aGVHD, cGVHD, and de novo cGVHD 
were regarded to be the secondary endpoints. The cumulative 
incidences of aGVHD, cGVHD, and de novo cGVHD were estimated 
for the respective type of GVHD, considering the event of interest 
and death without GVHD being the competing event. The cumulative 
incidences of RI, NRM, and GVHD were computed in a competing 
risks analysis, and the Gray test was being used to compare the 
groups with the delta method for confidence intervals. OS and RFS 
were analyzed with the Kaplan-Meier method; the log-rank test was 
used for univariate comparisons, while the Greenwood formula for 
computing confidence intervals.
Categorical variables were compared with the use of Chi-squared 
test or Fisher’s exact test. The proportional hazard assumption was 
verified using graphical methods [9, 10]. The uni- and multivariate 
analyses of prognostic factors were performed with the use of 
a Cox proportional hazards model to estimate hazard risk (HR) 
effect of variables on OS and RFS. Factors analyzed are listed in 
table I. Cause-specific HRs were investigated for RI, NRM, aGVHD, 
cGVHD, and de novo cGVHD [11]. Variables with p-value < 0.15 
in univariate analysis were included in multivariate model. All tests 
were two-sided. For multiple subgroup comparisons, the Bonferroni 
correction was applied. The inverted Kaplan-Meier method was used 
to calculate the median follow-up [12]. Analyses were performed by 




Patient characteristics are presented in table I. The majority of 
donors (74.4%) and recipients (79.2%) were EBV-seropositive. Both 
donor and recipient were seropositive in 1,541 cases (65.4%), while 
conversely both donor and recipient were seronegative in 276 cases 
(11.7%). With respect to the type of transplant, 66.7% had HCT from 
a matched family donor (MFD), 4.4% patients from a mismatched 
family donor (MMFD), and 28.9% HCT from an UD. The stem cell 
source included bone marrow ± cord blood (BM ± CB, 75.8%) or 
peripheral blood ± cord blood ± bone marrow (PB ± CB, 24.2%). 
T-cell depletion was used in vivo in 82.2%, while ex vivo in 6.4% of 
patients. Myeloablative conditioning (MAC) was used in 63.2%, and 
reduced-intensity regimen (RIC) in 36.8%. The median follow-up was 
4.6 (95%CI, 4.4–4.8) years.
Univariate analysis: EBV serostatus and transplant out-
comes
Transplants of EBV-seronegative recipients of grafts from EBV- 
-seronegative donors (EBV R−/D−) were of nonsignificant benefit 
when compared with EBV-seropositive recipients of grafts from any 
donors (EBV R+/D±) or EBV-seronegative recipients of grafts from 
EBV-seropositive donors for OS, RFS, NRM, and aGVHD (Tab. II, 
Fig. 1).
EBV-seropositive recipients of grafts from EBV-seropositive donors 
(EBV R+/D+) had nonsignificant inferior outcomes when compared 
with EBV-seronegative recipients of grafts from EBV-seronegative 
donors (EBV R−/D−): inferior OS (85.4% vs. 89.3%), inferior RFS 
(86.6% vs. 88.9%), increased NRM (10.2% vs. 5.8%), increased 
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Table I. Characteristics of patients and transplant










N (%) N (%) N (%) N (%) N (%)
Sex      
 Male  148 (53.6)  103 (48.4)  162 (49.8)  831 (53.9) 1,244 (52.8) 
 Female  128 (46.4)  110 (51.6)  163 (50.2)  710 (46.1) 1,111 (47.2) 
Age at this treatment (years)      
 Median 14.0 8.6 17.2 19.3 17.3 
 Range 0.5–69.8 0.5–62.8 1.0–67.8 0.9–77.7 0.5–77.7 
 N obs 276 213 325 1,541 2,355 
Age classes      
 <18 years  171 (62.0)  161 (75.6)  171 (52.6)  714 (46.3) 1,217 (51.7) 
 ≥18 years  105 (38.0)  52 (24.4)  154 (47.4)  827 (53.7) 1,138 (48.3) 
Diagnosis
 Acquired bone marrow failure  184 (66.7)  104 (48.8)  237 (72.9) 1,127 (73.1) 1,652 (70.1) 
 Hemoglobinopathies  92 (33.3)  109 (51.2)  88 (27.1)  414 (26.9)  703 (29.9) 
Interval between diagnosis and HCT      
 Median 8.2 17.0 11.2 11.4 11.3 
 Range 0.3–293.9 0.4–409.3 0.4–348.6 0.1–540.7 0.1–540.7 
 N obs 276 213 325 1,541 2,355 
Donor sex (N = 2,335/2,355)      
 Male  130 (47.1)  128 (60.7)  188 (58.8)  867 (56.7) 1,313 (56.2) 
 Female  146 (52.9)  83 (39.3)  132 (41.3)  661 (43.3) 1,022 (43.8) 
Age of the donor (N = 2,255/2,355)      
 Median 17.0 20.6 16.1 24.9 23.2 
 Range 0.0–58.5 0.0–65.9 0.0–66.8 0.0–76.2 0.0–76.2 
 N obs 261 207 309 1,478 2,255 
Recipient male – donor female match (2,335/2,355)      
 Other combinations  196 (71.0)  175 (82.9)  250 (78.1) 1,189 (77.8) 1,810 (77.5) 
 Recipient male – donor female  80 (29.0)  36 (17.1)  70 (21.9)  339 (22.2)  525 (22.5) 
Recipient–donor match      
 Recipient male – donor male  68 (24.6)  66 (31.3)  92 (28.8)  483 (31.6)  709 (30.4) 
 Recipient male – donor female  80 (29.0)  36 (17.1)  70 (21.9)  339 (22.2)  525 (22.5) 
 Recipient female – donor male  62 (22.5)  62 (29.4)  96 (30.0)  384 (25.1)  604 (25.9) 
 Recipient female – donor female  66 (23.9)  47 (22.3)  62 (19.4)  322 (21.1)  497 (21.3) 
CMV in patient and donor      
 -/-  117 (42.4)  53 (24.9)  90 (27.7)  333 (21.6)  593 (25.2) 
 -/+  29 (10.5)  46 (21.6)  15 (4.6)  148 (9.6)  238 (10.1) 
 ±  38 (13.8)  30 (14.1)  101 (31.1)  308 (20.0)  477 (20.3) 
 +/+  92 (33.3)  84 (39.4)  119 (36.6)  752 (48.8) 1,047 (44.5) 
Stem cell source
 BM  175 (63.4)  159 (74.6)  218 (67.1) 1,122 (72.8) 1,674 (71.1) 
 PB  47 (17.0)  40 (18.8)  52 (16.0)  357 (23.2)  496 (21.1) 
 BM + PB  22 (8.0)  3 (1.4)  0 (0.0)  6 (0.4)  31 (1.3) 
 CB  9 (3.3)  11 (5.2)  39 (12.0)  47 (3.0)  106 (4.5) 
 BM + CB  8 (2.9)  0 (0.0)  16 (4.9)  8 (0.5)  32 (1.4) 
 PB + CB  0 (0.0)  0 (0.0)  0 (0.0)  1 (0.1)  1 (0.0) 
 BM + PB + CB  15 (5.4)  0 (0.0)  0 (0.0)  0 (0.0)  15 (0.6) 
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aGVHD incidence (14.3% vs. 13.1%), and increased cGVHD 
incidence (17.3% vs. 16.6%). EBV-seropositive versus seronegative 
donor (D+ vs. D−) transplants had comparable outcomes; however, 
there was a trend toward higher cGVHD in EBV-seropositive donor 
transplants (Tab. II).
Pre-transplant recipient EBV-seronegativity had favorable significant 
influence on higher OS (p = 0.035) and lower incidence of NMR (p = 
0.017), however a trend was observed toward higher RI (p = 0.078) 
in comparison to EBV-seropositive status (Tab. II).
aGVHD grade II–IV was diagnosed in 320 (14.3%) patients. 
Cumulative incidence of aGVHD was 13.1% in EBV R−/D− and 
14.3% in R+/D+ cases (p = ns). The highest aGVHD was observed 
after R−/D+ transplants (16.0%). The 100-day cumulative incidence 
of grade II-IV aGVHD was comparable for EBV-seropositive versus 
seronegative donors (14.5% vs. 13.7%, p = ns) (Tab. II). Also, no 
impact of recipient EBV serostatus was observed.
cGVHD was diagnosed in 331 (16.9%) of the 1,958 evaluable 
patients. The number of cGVHD cases following aGVHD was 95 
(4.9%) and de novo cGVHD events was 236 (12.0%), as computed 
on 1,958 patients with available data for a/cGVHD. The highest 
cGVHD and de novo cGVHD was observed after R−D+ transplants 
(18.9% and 13.7%, respectively). There was a trend toward higher 
incidence of cGVHD in EBV D+ transplants in comparison to EBV 
D− transplants (p = 0.106); the impact of donor EBV serostatus was 
not significant for de novo cGVHD (Tab. II). No impact of recipient 
EBV serostatus was observed on the development of aGVHD or 
cGVHD. The cumulative incidences of cGVHD did not differ taking 
into account primary disease and EBV serostatus (data not shown).
Multivariate analysis
No impact of donor/recipient EBV serostatus on OS, RI, NRM, 
RFS, and aGVHD was shown (Tab. III). A trend was observed 
toward higher risk of cGVHD in HCT from EBV-seropositive donors 
(HR = 1.31; 95% CI = 0.97–1.78; p = 0.0810), and lower risk of 
cGVHD (HR = 0.75; 95% CI = 0.56–1.02; p = 0.0657) and de novo 
cGVHD (HR = 0.72; 95% CI = 0.50–1.02; p = 0.0633) in case of 
EBV-seropositive recipients (Tab. III).
Factors significantly contributing to an increased risk of aGVHD were: 
increasing age of donor and recipient (continuous variable), female 










N (%) N (%) N (%) N (%) N (%)
Donor type      
 Sibling  215 (77.9)  139 (65.3)  219 (67.4)  997 (64.7) 1,570 (66.7) 
 Mismatched relative  24 (8.7)  8 (3.8)  8 (2.5)  64 (4.2)  104 (4.4) 
 Unrelated  37 (13.4)  66 (31.0)  98 (30.2)  480 (31.1)  681 (28.9) 
HLA match      
 Identical sibling  210 (76.1)  128 (60.1)  211 (64.9)  948 (61.5) 1,497 (63.6) 
 Syngeneic  2 (0.7)  0 (0.0)  2 (0.6)  16 (1.0)  20 (0.8) 
 Matched other relative  3 (1.1)  11 (5.2)  6 (1.8)  33 (2.1)  53 (2.3) 
 Matched unrelated  11 (4.0)  13 (6.1)  21 (6.5)  102 (6.6)  147 (6.2) 
 Mismatched relative  24 (8.7)  8 (3.8)  8 (2.5)  64 (4.2)  104 (4.4) 
 Mismatched unrelated  3 (1.1)  7 (3.3)  21 (6.5)  51 (3.3)  82 (3.5) 
 Unrelated  23 (8.3)  46 (21.6)  56 (17.2)  327 (21.2)  452 (19.2) 
Ex-vivo T-cell depletion for HCT      
 No  263 (95.3)  197 (92.5)  315 (96.9) 1,430 (92.8) 2,205 (93.6) 
 Yes  13 (4.7)  16 (7.5)  10 (3.1)  111 (7.2)  150 (6.4) 
In-vivo T-cell depletion for HCT (N = 2,354/2,355)      
 No  95 (34.4)  47 (22.1)  70 (21.5)  206 (13.4)  418 (17.8) 
 Yes  181 (65.6)  166 (77.9)  255 (78.5) 1,334 (86.6) 1,936 (82.2) 
Intensity of conditioning      
 Standard  230 (83.3)  152 (71.4)  200 (61.5)  907 (58.9) 1,489 (63.2) 
 Reduced  46 (16.7)  61 (28.6)  125 (38.5)  634 (41.1)  866 (36.8) 
Year of this treatment      
 Median 2009 2010 2010 2010 2010 
 Range 1997–2016 1997–2016 1997–2016 1997–2016 1997–2016
 N obs 276 213 325 1,541 2,355 
HCT – hematopoietic cell transplantation; PB – peripheral blood; BM – bone marrow; CB – cord blood; N – number of patients
continued Table I. 
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Fig. 1. Impact of recipient (R)/donor (D) EBV serostatus on the 2-year transplant outcomes: (A) overall survival (OS); (B) relapse 
incidence (RI); (C) nonrelapse mortality (NRM); and (D) cumulative incidence of cGVHD
Patient EBV Total Failed 2-year OS HR (95% CI)
Negative 467 58 88.41 (85.02–91.08) 1.00
Positive 1763 289 85.38 (83.58–86.99) 1.35 (1.02–1.79)
p = 0.0354 p = 0.0363
A
Patient EBV Total Failed 2-year RI HR (95% Cl)
Negative 445 26 5.11 (3.26–7.55) 1.00
Positive 1668 66 3.23 (2.43–4.18) 0.69 (0.44–1.09)
p = 0.0784 p = 0.1086
B
Patient EBV Total Failed 2-year NRM HR (95% CI)
Negative 445 33 6.41 (4.33–9.04) 1.00
Positive 1668 188 10.04 (8.62–11.59) 1.55 (1.07–2.25)
p = 0.0179 p = 0.0199
C
Donor 
EBV Total Failed 2-year cGVHD HR (95% CI)
Negative 487 71 14.91 (11.80–18.36) 1.00
Positive 1471 260 17.50 (15.53–19.56) 1.27 (0.98–1.65)
p = 0.1063 p = 0.0733
D
Table II. Univariate analysis of an impact of EBV serostatus on overall survival (OS), relapse-free survival (RFS), relapse incidence 
(RI), nonrelapse mortality (NRM), acute and chronic GVHD (in% and 95%CI)
EBV Serostatus






















































































































p-value 0.0354 0.2892 0.0784 0.0179 0.9813 0.7059 0.4058
Two-year probabilities (%, 95% CI) are shown for OS, RFS, RI and NRM, cGVHD, de novo GVHD; 100-day probabilities are shown for aGVHD (grade II-IV), 
* probabilities were obtained using the Kaplan-Meier method, log-rank test was used to compare groups, † probabilities were obtained using the Cumulative In-
cidence method, Gray test was used to compare groups; OS – overall survival; RFS – relapse-free survival; RI – relapse incidence; NRM – nonrelapse mortality; 
aGVHD – acute graft-versus-host disease; cGVHD – chronic GVHD
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donor for male recipient, stem cell source from PB, mismatched donor, 
UD, no in vivo T-cell depletion, and earlier calendar year of transplant. 
Factors increasing risk of cGVHD included: increasing age of donor 
and recipient (continuous variable), female donor for male recipient, 
stem cell source from PB, no T-cell depletion (both ex vivo and in vivo), 
MMFD, UD, and earlier calendar year of transplant (Tab. III).
Discussion
This study was aimed to show the influence of donor/recipient EBV 
serostatus on transplant outcomes of patients with nonmalignant 
hematological disorders. We analyzed 2,55 patients with acquired 
bone marrow failure or hemoglobinopathies. Overall, no significant 
impact of donor and/or recipient EBV-seropositivity was shown on 
any transplant outcome. Only a trend toward increased risk of cGVHD 
was observed in the case of donor EBV-seropositivity (HR = 1.31, 
p = 0.08).
This is the third part of the study focused on the impact of EBV donor 
and recipient serostatus on transplant outcomes. In the first study of 
11,364 patients with acute leukemia after allo-HCT, we have proven that 
donor EBV-seropositivity increases the risk of aGVHD and cGVHD [1]. 
A 1.4-fold higher risk of cGVHD was observed in patients who 
received grafts from EBV-seropositive versus EBV-seronegative 
donors. The evidence that donor EBV-seropositivity increases the 
risk of cGVHD, and to a lesser extent also aGVHD, was a new and 
striking finding for patients with acute leukemias. No impact of EBV 
serostatus was found for other transplant outcomes.
In the second study of 12,931 patients with lymphomas or chronic 
malignancies undergoing allo-HCT, we have shown the impact 
of donor EBV-seropositivity on the development of cGVHD also 
in patients with lymphomas or chronic hematological malignant 
diseases [7]. However, in these group of patients, the role of 
recipient EBV-seropositivity was also shown, and in comparison 
with D−/R− EBV serostatus, all other combinations (D−/R+, D+/
R−, D+/R+) were associated with 1.21–1.26-fold increased risk of 
cGVHD. Nevertheless, the role of recipient EBV in pathogenesis 
of lymphomas should be considered. Again, no impact of EBV 
serostatus donor and/or recipient for other transplant outcomes 
was shown in multivariate analysis. Thus, the EBV-seronegative 
recipient with chronic malignancy or lymphoma undergoing allo-HCT 
can possibly benefit from selection of an EBV-seronegative donor 
in the context of cGVHD, while there is no preference in donor EBV 
serostatus for EBV-positive recipient.
In the present study of patients with nonmalignant hematological 
diseases, we observed the comparable increased risk of cGVHD 
in case of donor EBV-seropositivity, as it was found in previous two 
studies. In this study, however, only a trend was observed, but not 
statistical significance. On the other hand, the present study included 
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ns ns ns 0.45 (0.26–0.79)
0.0053
ns
In vivo T-cell depletion 
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ns ns 0.69 (0.51–0.93)
0.0161
ns ns ns ns
Year of HCT ns 0.95 (0.91–0.99)
0.0176





Shown are hazard ratios with 95% confidence interval (n = 2,230); p-value for the overall comparison; ns – not significant; Hazard ratio obtain from the Cox model 
were reported; § Cause-specific hazards were reported; # Bonferroni adjusted p-values are considered for Recipient (R)/donor(D) EBV serostatus, recipient (R)/
donor(D) CMV serostatus, and donor type, OS – overall survival; RFS – relapse-free survival; RI – relapse incidence; NRM – nonrelapse mortality; aGVHD – acute 
graft-versus-host disease; cGVHD – chronic GVHD
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2,355 patients, relatively smaller number than in previous reports. 
One can speculate that if the number of patients was higher as in 
the two other studies, we could have reached statistical significance. 
This limitation can be probably overcome in the future when more 
patients will be included in such an analysis.
Summarizing the results of 26,650 patients with various hematological 
diseases undergoing allo-HCT, reported in these three studies, we 
have found that the donor EBV seropositivity is associated with the 
development of cGVHD. This rises the potential possibility to prevent 
or treat cGVHD by controlling EBV infection.
The herpesvirus EBV is associated in the HCT setting with the 
development of PTLD which is almost exclusively of donor origin 
[13, 14]. Finding a role of donor EBV serostatus on the development 
of both cGHVD and PTLD rises the possibility of potential benefit of 
the selection of an EBV-seronegative donor, what might potentially 
reduce the risk of these two severe post-transplant complications. 
However, given the high prevalence of EBV, finding the 
EBV-seronegative adult donor would be highly challenging, so 
such a recommendation is rather more academic than practical [7]. 
The management recommended against EBV-PTLD in allo-HCT 
recipients is screening and monitoring for EBV by PCR, and pre-
emptive use of rituximab [15].
We have shown previously, that despite the impact of donor 
EBV-seropositivity on GVHD no increased GVHD-related deaths 
rate, and in consequence no effect on OS, RI, RFS, and NRM was 
observed in acute leukemia patients [1]. In another study, we have 
found the negative influence of EBV serology on transplant outcomes 
in lymphomas and chronic hematological malignancies in univariate 
analysis [7]. OS and RFS were decreased in EBV-seropositive 
recipients, while donor EBV serology had no impact on OS and RFS. 
This adverse effect of EBV cannot be fully overcome by allo-HCT, 
as both OS and RFS did not differ between transplants from EBV-
seropositive versus EBV-seronegative donors. Since children were 
more likely to be the R−/D− patients than R+/D+ combination (Tab. I), 
this could explain the impact in univariate analysis on OS/RFS while 
the cGVHD effect was not dependent on age. The role of EBV in 
pathogenesis of lymphomas possibly did not influence transplant 
outcomes negatively, since in multivariate analysis myeloid but not 
lymphoid malignancies had negative impact on OS, RI, RFS, and 
NRM. In both studies, neither donor nor recipient EBV serology had 
influence on NRM. This underlines that variety of pre- and post-
transplant factors contributing to final transplant outcomes.
The role of B-cell proliferation in pathogenesis of cGVHD is currently 
well known [16]. On the other hand, the efficacy of anti-B-cell 
approach with rituximab in therapy of steroid-refractory cGVHD was 
shown in meta-analysis [17]. This efficacy was also confirmed in 
Phase II study in first line therapy for cGVHD [18]. The effect of EBV 
was more obvious in the development of cGVHD rather than aGVHD, 
as it is related to B-cell recovery occurring usually after day +100.
Apart from the relatively low number of patients, our study has some 
other limitations. No data on pretransplant use of rituximab was 
documented. Prolonged immunosuppressive prophylaxis in patients 
with bone marrow failure theoretically could influence the development 
of GVHD. However, we did not find differences between patients with 
acquired bone marrow failure and hemoglobinopathies with respect 
to a/cGVHD. Also, the selection of patients was based mainly on the 
availability of data on recipient and donor EBV serostatus, so any 
specific transplant strategies could not be analyzed.
In conclusion, we were unable to show the impact of donor and/
or recipient EBV serostatus on transplant outcomes in patients 
with nonmalignant hematological disorders undergoing allo-HCT. 
A trend toward higher risk of cGVHD was observed in the case of 
EBV-seropositive donor, yet more data are necessary to draw a final 
conclusion.
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